The Bayesian-Based Area under the Curve of Vancomycin by Using a Single Trough Level: An Evaluation of Accuracy and Discordance at Tertiary Care Hospital in KSA

被引:0
作者
Alzahrani, Abdullah M. [1 ,2 ,3 ]
Naeem, Anjum [1 ,2 ,3 ]
Alzhrani, Rami M. [4 ]
Harbi, Manar A. [5 ]
Alghamdi, Sarah A. [5 ]
Karim, Shahid [6 ]
Ali, Ahmed S. [6 ]
Alsenaini, Ghusun [1 ,2 ,3 ]
Hasan, Hani [1 ,2 ,3 ]
Alkatheeri, Ayed A. [7 ]
Basudan, Samah S. [8 ]
Alzahrani, Yahya A. [2 ,7 ]
机构
[1] Minist Natl Guard Hlth Affairs, Pharmaceut Care Dept, Jeddah 22384, Saudi Arabia
[2] King Abdullah Int Med Res Ctr, Jeddah 21423, Saudi Arabia
[3] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Jeddah 22384, Saudi Arabia
[4] Taif Univ, Coll Pharm, Dept Pharmaceut & Ind Pharm, Taif 21944, Saudi Arabia
[5] King Abdulaziz Univ, Fac Pharm, Jeddah 21589, Saudi Arabia
[6] King Abdulaziz Univ, Fac Med, Dept Pharmacol, Jeddah 21589, Saudi Arabia
[7] East Jeddah Hosp, Drug Informat Ctr, Dept Pharm, Minist Hlth, Jeddah 23816, Saudi Arabia
[8] King Abdullah Med Complex, Minist Hlth, Dept Pharm, Jeddah 23816, Saudi Arabia
关键词
PrecisePK; AUC(0-24); vancomycin; discordance; trough level; Bayesian software; RESISTANT STAPHYLOCOCCUS-AUREUS; MINIMUM INHIBITORY CONCENTRATION; INFECTIONS; OUTCOMES; IMPACT;
D O I
10.3390/healthcare11030362
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The AUC(0-24) is the most accurate way to track the vancomycin level while the C-min is not an accurate surrogate. Most hospitals in Saudi Arabia are under-practicing the AUC-guided vancomycin dosing and monitoring. No previous work has been conducted to evaluate such practice in the whole kingdom. The current study objective is to calculate the AUC(0-24) using the Bayesian dosing software (PrecisePK), identify the probability of patients who receive the optimum dose of vancomycin, and evaluate the accuracy and precision of the Bayesian platform. This retrospective study was conducted at King Abdulaziz medical city, Jeddah. All adult patients treated with vancomycin were included. Pediatric patients, critically ill patients requiring ICU admission, patients with acute renal failure or undergoing dialysis, and febrile neutropenic patients were excluded. The AUC(0-24) was predicted using the PrecisePK platform based on the Bayesian principle. The two-compartmental model by Rodvold et al. in this platform and patients' dose data were utilized to calculate the AUC(0-24) and trough level. Among 342 patients included in the present study, the mean of the estimated vancomycin AUC(0-24) by the posterior model of PrecisePK was 573 +/- 199.6 mg, and the model had a bias of 16.8%, whereas the precision was 2.85 mg/L. The target AUC(0-24) (400 to 600 mg center dot h/L) and measured trough (10 to 20 mg/L) were documented in 127 (37.1%) and 185 (54%), respectively. Furthermore, the result demonstrated an increase in odds of AUC(0-24) > 600 mg center dot h/L among trough level 15-20 mg/L group (OR = 13.2, p < 0.05) as compared with trough level 10-14.9 mg/L group. In conclusion, the discordance in the AUC(0-24) ratio and measured trough concentration may jeopardize patient safety, and implantation of the Bayesian approach as a workable alternative to the traditional trough method should be considered.
引用
收藏
页数:10
相关论文
共 26 条
  • [1] Causes of vancomycin dosing error; problem detection and practical solutions; a retrospective, single-center, cross-sectional study
    Alzahrani, Abdullah M.
    Naeem, Anjum
    Alwadie, Ali F.
    Albogami, Khalid
    Alzhrani, Rami M.
    Basudan, Samah S.
    Alzahrani, Yahya A.
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (06) : 616 - 624
  • [2] Individualised medicine: why we need Bayesian dosing
    Donagher, Joni
    Martin, Jennifer H.
    Barras, Michael A.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 (05) : 593 - 600
  • [3] Finch NA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01293-17, 10.1128/aac.01293-17]
  • [4] Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia
    Ghosh, N.
    Chavada, R.
    Maley, M.
    van Hal, S. J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (12) : O1098 - O1105
  • [5] Hale Cory M, 2017, J Pharm Pract, V30, P329, DOI 10.1177/0897190016642692
  • [6] Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment
    Hassoun, Ali
    Linden, Peter K.
    Friedman, Bruce
    [J]. CRITICAL CARE, 2017, 21 : 211
  • [7] Bacteremia due to Methicillin-Resistant Staphylococcus aureus New Therapeutic Approaches
    Holubar, Marisa
    Meng, Lina
    Deresinski, Stan
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2016, 30 (02) : 491 - +
  • [8] High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis
    Jacob, Jesse T.
    DiazGranados, Carlos A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (02) : E93 - E100
  • [9] Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin
    Lee, Brian, V
    Fong, Gary
    Bolaris, Michael
    Neely, Michael
    Minejima, Emi
    Kang, Amy
    Lee, Grace
    Gong, Cynthia L.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (09) : 1346.e1 - 1346.e7
  • [10] Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing
    Neely, Michael N.
    Kato, Lauren
    Youn, Gilmer
    Kraler, Lironn
    Bayard, David
    van Guilder, Michael
    Schumitzky, Alan
    Yamada, Walter
    Jones, Brenda
    Minejima, Emi
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (02)